1. Home
  2. CUK vs ILMN Comparison

CUK vs ILMN Comparison

Compare CUK & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carnival Plc ADS ADS

CUK

Carnival Plc ADS ADS

HOLD

Current Price

$25.17

Market Cap

41.7B

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$124.65

Market Cap

19.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CUK
ILMN
Founded
1972
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Marine Transportation
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.7B
19.0B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
CUK
ILMN
Price
$25.17
$124.65
Analyst Decision
Strong Buy
Hold
Analyst Count
21
17
Target Price
$35.57
$124.24
AVG Volume (30 Days)
2.9M
1.5M
Earning Date
03-27-2026
05-07-2026
Dividend Yield
0.58%
N/A
EPS Growth
N/A
170.87
EPS
N/A
5.45
Revenue
N/A
$4,343,000,000.00
Revenue This Year
$8.05
$6.54
Revenue Next Year
$4.08
$5.49
P/E Ratio
$16.36
$23.16
Revenue Growth
N/A
N/A
52 Week Low
$13.65
$68.70
52 Week High
$33.72
$155.53

Technical Indicators

Market Signals
Indicator
CUK
ILMN
Relative Strength Index (RSI) 41.56 49.06
Support Level $23.26 $124.27
Resistance Level $27.88 $126.00
Average True Range (ATR) 0.97 4.43
MACD 0.15 0.75
Stochastic Oscillator 47.91 68.47

Price Performance

Historical Comparison
CUK
ILMN

About CUK Carnival Plc ADS ADS

Carnival is the largest global cruise company, with more than 90 ships in service. Its portfolio of brands includes Carnival Cruise Line, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard in the United Kingdom; Aida in Germany; and Costa Cruises in Southern Europe. It recently folded its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted nearly 14 million guests in 2025.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: